Hepatocellular Carcinoma (HCC)HCC-MPDSNCT07700082
HCC-MPDS Multimodal Deep Learning Prognostic Model for Resectable HCC
An observational study of Hepatocellular Carcinoma (HCC), run by Anhui Provincial Hospital at 1 site in China.
Trial summary
This is a completed multi-center retrospective observational study focusing on patients who received curative surgical resection for hepatocellular carcinoma (HCC). We collected anonymized historical clinical data, preoperative gadoxetic acid-enhanced MRI scans and digital pathological whole-slide images from three… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hepatocellular Carcinoma (HCC)
- How many people
- 555 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2020to 1 Jan 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: The study population consists of 555 adult patients with pathologically confirmed hepatocellular carcinoma who underwent curative hepatectomy. All subjects had complete preoperative gadoxetic acid-enhanced MRI, digital pathological whole-slide images, clinical records and long-term follow-up data. Cases were retrospectively collected from three Chinese tertiary hospitals and the public TCGA-LIHC database, excluding patients with incomplete imaging, pathological or follow-up information.
Who may be able to join
- patients with pathologically confirmed hepatocellular carcinoma (HCC);
- patients accepting curative surgical resection (SR) without preoperative adjuvant treatment;
- MRI were performed two weeks before surgery.
Who cannot join
- incomplete clinical information;
- incomplete or suboptimal quality of preoperative MRI imaging data;
- unavailable or poor-quality pathological whole slide images (WSIs);
- incomplete follow-up data.
Trial locations and contacts
1 site in 1 country.
China1 site
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, 230000
About this study
Official title: Multimodal Hybrid Deep Learning-based Prognostic Decision System to Guide Adjuvant Therapy in Hepatocellular Carcinoma After Surgical Resection
This is a completed multi-center retrospective observational study focusing on patients who received curative surgical resection for hepatocellular carcinoma (HCC). We collected anonymized historical clinical data, preoperative gadoxetic acid-enhanced MRI scans and digital pathological whole-slide images from three Chinese medical centers and the public TCGA-LIHC database. We developed a multimodal hybrid deep learning prognostic model (named HCC-MPDS) integrating multi-source medical data to stratify HCC patients into high-risk and low-risk recurrence groups after surgery. The primary goal of this study is to compare postoperative recurrence-free survival (RFS) and overall survival (OS) between the two risk subgroups, and evaluate whether this artificial intelligence prediction system can help clinicians identify patients who may benefit from postoperative adjuvant therapy. No new experimental drugs or interventional treatments were provided to participants; all data were retrospectively extracted from archived medical records under institutional ethics approval, with waived written informed consent for de-identified historical samples and images.
- Conditions
- Hepatocellular Carcinoma (HCC)
- Medical subject headings
- Carcinoma, Hepatocellular
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| MPDS High-risk patients (risk score > -1.76) | Not described | |
| MPDS Low-risk patients (risk score ≤ -1.76) | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Recurrence-Free Survival (RFS)
Time from surgical resection to first local/regional recurrence, distant metastasis or all-cause death, whichever occurs first
Measured: Up to 60 months after hepatectomy
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jul 2026
- Study start1 Jan 2020
- Primary completion31 Dec 2024
- Study completion1 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hepatocellular Carcinoma (HCC)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 555 participants (actual)
Sponsor and investigators
- Lead sponsor
- Anhui Provincial Hospital
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Lianxin Liu，PhD, Anhui Provincial Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07700082
- Sponsor's protocol ID
- 2026KY245
- Acronym
- HCC-MPDS
- Status last verified
- Jul 2026
- First submitted
- 7 Jul 2026
- Last updated
- 13 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multimodal Hybrid Deep Learning-based Prognostic Decision System to Guide Adjuvant Therapy in Hepatocellular Carcinoma After Surgical Resection
- ClinicalTrials.gov ID
- NCT07700082
- Acronym / sponsor ID
- HCC-MPDS / 2026KY245
- Conditions
- Hepatocellular Carcinoma (HCC)
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 555 participants (actual)
- Lead sponsor
- Anhui Provincial HospitalOther government
- Study start
- 1 Jan 2020 (actual)
- Primary completion
- 31 Dec 2024 (actual)
- Study completion
- 1 Jan 2026 (actual)
- First posted
- 13 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a completed multi-center retrospective observational study focusing on patients who received curative surgical resection for hepatocellular carcinoma (HCC). We collected anonymized historical clinical data, preoperative gadoxetic acid-enhanced MRI scans and digital pathological whole-slide images from three Chinese medical centers and the public TCGA-LIHC database. We developed a multimodal hybrid deep learning prognostic model (named HCC-MPDS) integrating multi-source medical data to stratify HCC patients into high-risk and low-risk recurrence groups after surgery. The primary goal of this study is to compare postoperative recurrence-free survival (RFS) and overall survival (OS) between the two risk subgroups, and evaluate whether this artificial intelligence prediction system can help clinicians identify patients who may benefit from postoperative adjuvant therapy. No new experimental drugs or interventional treatments were provided to participants; all data were retrospectively extracted from archived medical records under institutional ethics approval, with waived written informed consent for de-identified historical samples and images.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| MPDS High-risk patients (risk score > -1.76) | – | – |
| MPDS Low-risk patients (risk score ≤ -1.76) | – | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- The study population consists of 555 adult patients with pathologically confirmed hepatocellular carcinoma who underwent curative hepatectomy. All subjects had complete preoperative gadoxetic acid-enhanced MRI, digital pathological whole-slide images, clinical records and long-term follow-up data. Cases were retrospectively collected from three Chinese tertiary hospitals and the public TCGA-LIHC database, excluding patients with incomplete imaging, pathological or follow-up information.
Key inclusion criteria (3 listed)
- patients with pathologically confirmed hepatocellular carcinoma (HCC);
- patients accepting curative surgical resection (SR) without preoperative adjuvant treatment;
- MRI were performed two weeks before surgery.
Key exclusion criteria (4 listed)
- incomplete clinical information;
- incomplete or suboptimal quality of preoperative MRI imaging data;
- unavailable or poor-quality pathological whole slide images (WSIs);
- incomplete follow-up data.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Recurrence-Free Survival (RFS)
Time frame: Up to 60 months after hepatectomy
Time from surgical resection to first local/regional recurrence, distant metastasis or all-cause death, whichever occurs first
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Hepatocellular Carcinoma (HCC)
Not yet recruitingPhase 1
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
Hepatocellular Carcinoma, Renal Cell Carcinoma
RecruitingObservational study
Observational Study Protocol: LIVER-R
Hepatobiliary Cancers
Enrolling by invitationPhase 3
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Cancer, Renal Cell Carcinoma (RCC)
Active, not recruiting
BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma Non-resectable
Active, not recruitingPhase 1
Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hepatocellular Carcinoma (HCC), run by Anhui Provincial Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Recurrence-Free Survival (RFS) (time frame: Up to 60 months after hepatectomy). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2026.